Stock listing
NASDAQ:RLAY Relay Therapeutics, Inc. Stock
Home listing (NASDAQ) of Relay Therapeutics, Inc.
Follow Relay Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:RLAY
$16.12 USD -0.39 (-2.4%)
Close on Nov 20, 2026
- Day range
- $15.17 – $16.32 USDNov 20, 2026
- Volume
- 3.98M sharesNov 20, 2026
- Market cap
- $3.56B USDAt the close on Nov 20, 2026 · price × 221.0M shares outstanding
- 52-week range
- $6.28 – $21.27 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $54.29M USDMedian day 2.77M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:RLAY · Home | $16.12 USD | -0.39 (-2.4%) | 3,975,151 | $15.59 | $16.32 | $15.17 | $16.51 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:RLAY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $16.12 | -0.39 | -2.4% | $15.59 | $16.32 | $15.17 | 3,975,151 | |
| $16.51 | +0.04 | +0.2% | $16.41 | $17.14 | $16.23 | 2,426,042 | |
| $16.47 | -0.80 | -4.6% | $17.20 | $17.42 | $16.39 | 2,569,179 | |
| $17.27 | -0.82 | -4.5% | $17.81 | $18.07 | $17.22 | 1,651,500 | |
| $18.09 | +0.01 | +0.1% | $17.95 | $18.25 | $17.28 | 1,478,164 | |
| $18.08 | -1.64 | -8.3% | $19.51 | $19.51 | $18.05 | 2,764,336 | |
| $19.72 | -0.22 | -1.1% | $20.01 | $20.21 | $19.69 | 1,932,007 | |
| $19.94 | -0.45 | -2.2% | $20.00 | $20.96 | $19.65 | 2,402,109 | |
| $20.39 | +1.79 | +9.6% | $19.08 | $20.64 | $18.71 | 3,847,791 | |
| $18.60 | +1.60 | +9.4% | $17.14 | $18.72 | $16.66 | 3,194,720 | |
| $17.00 | -1.03 | -5.7% | $17.71 | $18.21 | $16.53 | 4,720,932 | |
| $18.03 | +0.59 | +3.4% | $17.57 | $18.27 | $17.08 | 3,729,806 | |
| $17.44 | +0.16 | +0.9% | $17.52 | $18.00 | $17.28 | 3,176,095 | |
| $17.28 | -1.07 | -5.8% | $18.39 | $18.51 | $17.24 | 2,853,981 | |
| $18.35 | -1.12 | -5.8% | $19.09 | $19.48 | $18.01 | 3,595,892 | |
| $19.47 | -0.22 | -1.1% | $19.80 | $20.20 | $19.31 | 1,944,976 | |
| $19.69 | +0.85 | +4.5% | $18.62 | $19.71 | $18.60 | 2,807,593 | |
| $18.84 | +0.72 | +4.0% | $18.18 | $18.95 | $17.82 | 2,258,106 | |
| $18.12 | -0.06 | -0.3% | $18.33 | $18.66 | $17.97 | 1,585,695 | |
| $18.18 | -0.16 | -0.9% | $18.03 | $18.27 | $17.68 | 1,898,900 | |
| $18.34 | -0.07 | -0.4% | $18.28 | $18.71 | $18.02 | 1,722,000 | |
| $18.41 | -0.04 | -0.2% | $18.61 | $19.03 | $18.19 | 1,598,200 | |
| $18.45 | +1.36 | +8.0% | $17.03 | $18.69 | $17.01 | 1,976,100 | |
| $17.09 | +0.81 | +5.0% | $16.53 | $17.21 | $16.38 | 1,748,700 | |
| $16.28 | -1.02 | -5.9% | $17.17 | $17.17 | $16.13 | 2,366,600 | |
| $17.30 | +0.24 | +1.4% | $17.15 | $17.56 | $17.07 | 2,117,100 | |
| $17.06 | -0.30 | -1.7% | $17.02 | $17.77 | $16.90 | 2,936,800 | |
| $17.36 | -0.62 | -3.4% | $17.84 | $17.94 | $17.27 | 1,706,400 | |
| $17.98 | +0.10 | +0.6% | $17.77 | $18.33 | $17.53 | 2,091,000 | |
| $17.88 | +0.47 | +2.7% | $17.01 | $18.50 | $17.01 | 1,764,500 | |
| $17.41 | -0.54 | -3.0% | $17.71 | $17.97 | $16.87 | 4,332,100 | |
| $17.95 | -0.79 | -4.2% | $18.40 | $18.54 | $17.85 | 3,433,000 | |
| $18.74 | -0.65 | -3.4% | $19.50 | $19.50 | $18.17 | 3,879,800 | |
| $19.39 | +0.43 | +2.3% | $19.00 | $19.40 | $18.29 | 2,936,000 | |
| $18.96 | +0.47 | +2.5% | $18.71 | $19.13 | $18.60 | 2,771,000 | |
| $18.49 | +0.44 | +2.4% | $18.02 | $19.08 | $17.86 | 2,824,200 | |
| $18.05 | -0.31 | -1.7% | $18.39 | $18.72 | $17.93 | 2,782,500 | |
| $18.36 | +0.67 | +3.8% | $17.65 | $18.48 | $17.52 | 3,589,000 | |
| $17.69 | +0.22 | +1.3% | $17.10 | $17.88 | $17.05 | 1,843,500 | |
| $17.47 | -0.26 | -1.5% | $17.94 | $18.01 | $17.42 | 2,983,600 | |
| $17.73 | -0.30 | -1.7% | $18.09 | $18.09 | $17.41 | 3,675,000 | |
| $18.03 | -1.32 | -6.8% | $19.15 | $19.23 | $17.22 | 4,705,600 | |
| $19.35 | +1.16 | +6.4% | $18.43 | $19.48 | $18.21 | 3,632,000 | |
| $18.19 | -0.65 | -3.5% | $19.07 | $19.17 | $18.05 | 3,029,900 | |
| $18.84 | -0.35 | -1.8% | $19.25 | $19.40 | $18.68 | 10,076,100 | |
| $19.19 | +0.35 | +1.9% | $19.45 | $19.69 | $19.07 | 3,095,700 | |
| $18.84 | -0.13 | -0.7% | $18.97 | $19.22 | $18.62 | 2,116,700 | |
| $18.97 | -0.09 | -0.5% | $19.05 | $19.09 | $18.64 | 2,742,800 | |
| $19.06 | +0.19 | +1.0% | $18.90 | $19.43 | $18.88 | 2,400,200 | |
| $18.87 | -0.02 | -0.1% | $19.17 | $19.35 | $18.68 | 4,164,400 | |
| $18.89 | +0.23 | +1.2% | $18.30 | $19.11 | $18.10 | 3,000,700 | |
| $18.66 | -0.45 | -2.4% | $18.76 | $19.19 | $18.54 | 6,061,100 | |
| $19.11 | +0.07 | +0.4% | $18.78 | $19.28 | $18.31 | 5,029,400 | |
| $19.04 | +0.03 | +0.2% | $18.85 | $19.26 | $18.68 | 2,054,800 | |
| $19.01 | +0.50 | +2.7% | $18.55 | $19.10 | $18.34 | 2,716,600 | |
| $18.51 | +0.02 | +0.1% | $18.70 | $19.27 | $18.29 | 2,107,900 | |
| $18.49 | +0.11 | +0.6% | $18.15 | $18.68 | $17.96 | 1,598,400 | |
| $18.38 | -0.39 | -2.1% | $18.54 | $18.64 | $18.03 | 3,784,700 | |
| $18.77 | -0.65 | -3.3% | $19.15 | $19.30 | $18.63 | 2,762,900 | |
| $19.42 | -0.04 | -0.2% | $19.23 | $19.68 | $19.16 | 2,394,400 | |
| $19.46 | -1.11 | -5.4% | $19.95 | $20.12 | $19.19 | 2,936,600 | |
| $20.57 | +0.81 | +4.1% | $20.18 | $20.77 | $20.05 | 2,744,194 | |
| $19.76 | +0.32 | +1.6% | $19.16 | $20.03 | $18.60 | 2,639,387 | |
| $19.44 | -0.26 | -1.3% | $19.92 | $20.17 | $19.18 | 2,965,800 | |
| $19.70 | -1.04 | -5.0% | $20.36 | $20.50 | $19.42 | 2,788,700 |
- Ticker
- NASDAQ:RLAY
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 83 slides
Latest news
Relay Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Updates
Nov 4, 2026
Closed $17.00 (-5.7%) on Nov 5, 2026
Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November
Nov 2, 2026
Closed $17.44 (+0.9%) on Nov 3, 2026
Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026
Oct 28, 2026
Closed $19.47 (-1.1%) on Oct 29, 2026
Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates
Aug 6, 2026
Closed $19.77 (+0.1%) on Aug 7, 2026
Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026
Jul 30, 2026
Closed $18.83 (-3.2%) on Jul 31, 2026
Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies
May 19, 2026
Closed $12.07 (-0.2%) on May 19, 2026
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates
May 5, 2026
Closed $12.92 (-0.6%) on May 6, 2026
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
Apr 29, 2026
Closed $12.96 (+3.1%) on Apr 30, 2026
Relay Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 112 in all · newest Nov 4, 2026 · oldest 2020
- Decks
- 25 decks · latest August 2026
Where Relay Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:RLAY · Home listing · This page | NASDAQ | United States | USD |
| BOATS:RLAY | BOATS | United States | USD |
Valuation
EV/sales 265× against a median of 83.7×: the highest of 4 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $2.74B USD
- P/E
- Loss
- EV/sales
- 265×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 4.3×
- Gross margin
- Revenue too small
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.48
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Relay Therapeutics, Inc. · NASDAQ:RLAY | US$3.56B | US$2.74B | n/a | 265× | n/a | 4.3× | n/a | 0.0× | 1.48 |
| CRISPR Therapeutics AG · NASDAQ:CRSP | US$3.79B | US$2.11B | n/a | 83.7× | n/a | 2.3× | n/a | 0.4× | 1.64 |
| Tango Therapeutics, Inc. · NASDAQ:TNGX | US$3.68B | US$2.74B | n/a | n/a | n/a | 3.8× | n/a | 0.0× | 1.41 |
| Xenon Pharmaceuticals Inc. · NASDAQ:XENE | US$3.64B | US$2.70B | n/a | n/a | n/a | 3.2× | n/a | 0.0× | 0.80 |
| Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Class A · SSE:688336 | US$3.56B | US$3.42B | 7.6× | 5.1× | n/a | 2.7× | 69.9% | 0.0× | n/a |
| Enliven Therapeutics, Inc. · NASDAQ:ELVN | US$3.42B | US$2.54B | n/a | n/a | n/a | 3.9× | n/a | 0.0× | 0.89 |
| Disc Medicine, Inc. · NASDAQ:IRON | US$3.42B | US$2.80B | n/a | n/a | n/a | 5.7× | n/a | 0.1× | 0.94 |
| Viridian Therapeutics, Inc. · NASDAQ:VRDN | US$3.40B | US$2.69B | n/a | 102× | n/a | 5.9× | n/a | 0.4× | 1.00 |
| Parabilis Medicines, Inc. · NASDAQ:PBLS | US$3.39B | US$2.53B | n/a | n/a | n/a | 3.4× | n/a | 0.0× | n/a |
| Caliway Biopharmaceuticals Co Ltd · TWSE:6919 | US$3.38B | US$3.27B | n/a | n/a | n/a | 12.7× | n/a | 0.0× | n/a |
| Amylyx Pharmaceuticals, Inc. · NASDAQ:AMLX | US$3.35B | US$2.58B | n/a | n/a | n/a | 4.4× | n/a | 0.0× | 1.21 |
| Median of the others | US$3.42B | US$2.69B | 7.6× | 83.7× | 3.8× | 69.9% | 0.0× | 1.00 |
Forecasts
9 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 28.25 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.56 · 11 analysts
- Revenue, year to Dec 2026
- 6.9M · 11 analysts
Team and board
| Officer | Role |
|---|---|
| Sanjiv K. Patel | President & Chief Executive Officer |
| Tom Catinazzo | Chief Financial Officer |
| Don Bergstrom | President, R&D |
| Imogen Pryce | Chief Operating Officer, R&D |
| Soo-Yeun Lim | Senior Vice President, General Counsel |
| Eunice Kwak | SVP, Breast Cancer Global Medical Lead |
| Jim Watters | Chief Scientific Officer |
| Mahesh Padval | Chief Pharmaceutical Development Officer |
| Peter Rahmer | Chief Corporate Development Officer |
| Shannon Campbell | Head of Commercial |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −5.7% |
| Q2 2026 | Aug 6, 2026 · After close | +0.1% |
| Q1 2026 | May 5, 2026 · After close | −0.6% |
| Q4 2025 | Feb 26, 2026 | +11.3% |
| Q3 2025 | Nov 6, 2025 · After close | −7.3% |
| Q2 2025 | Aug 7, 2025 · After close | −7.7% |
| Q1 2025 | May 5, 2025 · After close | −5.1% |
| Q4 2024 | Feb 20, 2025 · After close | −4.2% |
| Q3 2024 | Nov 6, 2024 · After close | −1.8% |
| Q2 2024 | Aug 6, 2024 · After close | −7.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | −0.6% |
| Q4 2023 | Feb 22, 2024 · After close | −5.4% |
| Q3 2023 | Nov 2, 2023 · After close | +1.6% |
| Q2 2023 | Aug 8, 2023 · After close | +0.1% |
| Q1 2023 | May 4, 2023 · After close | +0.5% |
| Q4 2022 | Feb 23, 2023 · After close | −2.1% |
| Q3 2022 | Nov 3, 2022 · After close | −2.1% |
| Q2 2022 | Aug 4, 2022 · After close | +3.0% |
| Q1 2022 | May 5, 2022 · After close | −11.5% |
| Q4 2021 | Feb 24, 2022 · After close | +5.3% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 83 slides | August 2026 |
| Technical Presentation (May 2026) | Technical | 12 slides | May 20, 2026 |
| Corporate Update (May 2026) | Corporate update | 25 slides | May 19, 2026 |
| Corporate Update (April 2026) | Corporate update | 25 slides | Apr 27, 2026 |
| Technical Presentation (March 2026) | Technical | 13 slides | Mar 16, 2026 |
| Technical Presentation (March 2026) | Technical | 31 slides | March 2026 |
| J.P. Morgan Healthcare Conference 2025 | Conference | 29 slides | Jan 13, 2025 |
| 2024 San Antonio Breast Cancer Symposium (SABCS) | Conference | 39 slides | Dec 11, 2024 |
| Corporate Update (September 2024) | Corporate update | 34 slides | Sep 9, 2024 |
| Investor Day (June 2024) | Investor day | 66 slides | Jun 6, 2024 |
All 25 decks
IPO
Priced at US$20.00 a share on Jul 15, 2020.
- Price
- US$20.00 a share
- Shares offered
- 20,000,000 shares of common stock
- Offering size
- US$400 million
- Underwriters' option
- Up to 3,000,000 more shares
- Underwriters
- J.P. Morgan, Goldman Sachs & Co. LLC, Cowen, Guggenheim Securities · In the order on the cover
- Shares delivered
- On or about Jul 20, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | May 22, 2020 |
| Filed publicly | Jun 24, 2020 |
| Amended 4 times | Newest Jul 15, 2020 |
| Shares registered with an exchange | Jul 13, 2020 |
| Declared effective by the SEC | Jul 15, 2020 |
| Final prospectus, with the price | Jul 16, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Jul 16, 2020 |
| EFFECT · Notice that a registration is effective | Jul 15, 2020 |
| S-1/A · Registration statement, amended | Jul 15, 2020 |
| CERT · Exchange's certificate of listing | Jul 15, 2020 |
| S-1/A · Registration statement, amended | Jul 15, 2020 |
| CORRESP · Letter to the SEC | Jul 14, 2020 |
| S-1/A · Registration statement, amended | Jul 14, 2020 |
| UPLOAD · Letter from the SEC | Jul 14, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Jul 13, 2020 |
| CORRESP · Letter to the SEC | Jul 13, 2020 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Jul 13, 2020 |
| CORRESP · Letter to the SEC | Jul 9, 2020 |
| S-1/A · Registration statement, amended | Jul 9, 2020 |
| UPLOAD · Letter from the SEC | Jul 8, 2020 |
| CORRESP · Letter to the SEC | Jun 25, 2020 |
| CORRESP · Letter to the SEC | Jun 24, 2020 |
| S-1 · Registration statement | Jun 24, 2020 |
| DRS/A · Draft registration statement, amended | Jun 22, 2020 |
| UPLOAD · Letter from the SEC | Jun 19, 2020 |
| DRS · Draft registration statement | May 22, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Jul 16, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15.4M | 10.0M | 25.5M | 1.38M | 3.03M | 82.7M | 0 | 0 |
| Cost of revenue | 3.56M | 315.4M | 326.4M | 243.0M | 169.4M | 3.55M | 2.85M | 2.15M |
| Gross profit | 11.8M | -305.4M | -300.8M | -241.6M | -166.4M | 79.1M | -2.85M | -2.15M |
| Research and development | 261.4M | 319.1M | 330.0M | 246.4M | 172.7M | 99.9M | 70.3M | 41.0M |
| Selling, general and administrative | 56.7M | 76.0M | 74.3M | 65.1M | 55.5M | 38.6M | 13.7M | 8.86M |
| Operating income | -302.7M | -372.5M | -373.0M | -299.3M | -364.7M | -55.8M | -84.0M | -49.9M |
| Depreciation and amortization | 3.56M | 5.46M | 5.27M | 4.13M | 3.92M | 3.55M | 2.85M | 2.15M |
| EBITDA | -299.2M | -367.0M | -367.7M | -295.1M | -360.8M | -52.2M | -81.2M | -47.7M |
| Interest expense | 8.77M | 826.0K | 0 | 0 | 0 | |||
| Income before tax | -276.5M | -337.7M | -342.0M | -290.5M | -363.9M | -52.4M | -75.3M | -48.8M |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.10M |
| Net income | -276.5M | -337.7M | -342.0M | -290.5M | -363.9M | -52.4M | -75.3M | -48.8M |
| Earnings per share, basic | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | -21.82 | -19.63 |
| Earnings per share, diluted | -1.61 | -2.36 | -2.79 | -2.59 | -3.82 | -5.40 | -21.82 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 84.0M | 124.3M | 143.7M | 151.8M | 280.1M | 447.6M | 42.0M | 421.5M |
| Short-term investments | 470.5M | 657.0M | 606.4M | 847.1M | 678.0M | 230.4M | 313.9M | 0 |
| Receivables | 0 | 306.0K | 403.0K | 75.0M | ||||
| Inventory | 12.1M | -682.5M | -238.1M | |||||
| Current assets | 578.3M | 809.2M | 770.1M | 1.02B | 976.2M | 770.1M | 360.5M | 424.1M |
| Property, plant and equipment | 1.73M | 5.91M | 10.9M | 11.6M | 6.54M | 6.25M | 8.09M | 3.63M |
| Total assets | 621.3M | 871.3M | 844.0M | 1.10B | 1.01B | 799.8M | 393.1M | 428.6M |
| Accounts payable | 7.71M | 14.1M | 9.21M | 10.6M | 8.28M | 6.35M | 6.99M | 4.71M |
| Current liabilities | 25.6M | 50.7M | 30.3M | 63.7M | 24.3M | 13.6M | 12.0M | 6.87M |
| Total debt | 32.5M | 48.5M | 53.5M | 57.7M | 22.9M | 24.4M | 24.8M | 178.0K |
| Total liabilities | 54.3M | 93.5M | 92.0M | 149.6M | 110.6M | 36.5M | 35.7M | 539.5M |
| Shareholders' equity | 567.1M | 777.8M | 752.0M | 950.2M | 897.8M | 763.3M | -180.4M | -110.9M |
| Shares outstanding | 173.9M | 167.8M | 127.5M | 121.1M | 108.2M | 89.9M | 4.04M | 2.49M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -235.5M | -249.1M | -300.3M | -229.5M | -74.4M | -102.5M | -66.1M | -44.1M |
| Capital spending | -410.0K | -2.02M | -4.13M | -9.06M | -3.47M | -1.93M | -8.00M | -1.69M |
| Free cash flow | -235.9M | -251.1M | -304.4M | -238.6M | -77.9M | -104.4M | -74.1M | -45.8M |
| Cash from investing | 192.8M | -41.1M | 257.6M | -188.7M | -479.5M | 81.7M | -319.0M | -1.68M |
| Cash from financing | 1.60M | 270.2M | 34.8M | 289.9M | 388.1M | 426.5M | 5.61M | 395.0M |
| Share buybacks | 1.08M | 1.48M | 1.69M | 5.88M | 429.0M | 5.61M | -82.0K | |
| Change in cash | -41.1M | -20.0M | -7.93M | -128.3M | -165.8M | 405.7M | -379.6M | 349.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 18, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 16, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Oct 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 25, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 18, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 10, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 7, 2026 | Big-stake notice | SEC |
| 424B5 · Prospectus | Aug 6, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Aug 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 31, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jul 2, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 30, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 22, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 10, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 9, 2026 | Meeting outcome | SEC |
| 8-K · Current report | May 21, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 21, 2026 | Offer document | SEC |
| 424B5 · Prospectus | May 19, 2026 | Offer document | SEC |
| 8-K · Current report | May 19, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 14, 2026 | Other filings | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 28, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 16, 2026 | Meeting notice | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 13, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 19, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 16, 2026 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Mar 11, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2026 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2026 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Feb 3, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 29, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 7, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 6, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 6, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 29, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 14, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 29, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 10, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 11, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 11, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 6, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 4, 2025 | Material contract | SEC |
| SCHEDULE 13G · Big-stake notice | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2025 | Results | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 30, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 30, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Apr 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Apr 24, 2025 | Insider trade | SEC |
| ARS · Annual report to shareholders | Apr 23, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2025 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 17, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 31, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 27, 2025 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 20, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Feb 26, 2025 | Offer document | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 30, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 29, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 28, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 23, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 23, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 22, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 21, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 13, 2025 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 6, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 3, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 31, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 27, 2024 | Other filings | SEC |
| 4 · Change in ownership | Dec 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 16, 2024 | Other filings | SEC |
| 8-K · Current report | Dec 11, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 30, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Oct 29, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Oct 28, 2024 | Other filings | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Oct 1, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 27, 2024 | Other filings | SEC |
| 8-K · Current report | Sep 11, 2024 | Material contract | SEC |
| 424B5 · Prospectus | Sep 11, 2024 | Offer document | SEC |
| 424B5 · Prospectus | Sep 9, 2024 | Offer document | SEC |
This page holds 200 of 562 filings. Open Filings
Cap table
Built by 6ix from Relay Therapeutics, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 220,959,470
- Fully diluted
- 220,959,470
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 220,959,470 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 220,959,470 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Habib Joseph Dable Other companies: Tyra Biosciences, Inc. (Director · Since at least Apr 16, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Day One Biopharmaceuticals Inc (Director · Since at least Jan 17, 2024); PepGen Inc. (Director · Since at least Sep 20, 2022); Blueprint Medicines Corp (Director · Since at least Jun 23, 2022); Jade Biosciences, Inc. (Director · Jul 10, 2023 – Jun 5, 2024 · Past); Albireo Pharma Inc (Director · Aug 8, 2022 – Mar 2, 2023 · Past); Acceleron Pharma Inc (CEO and President, Director · Jan 4, 2021 – Nov 19, 2021 · Past) | Director · Since at least Nov 4, 2025 |
| Alexis Borisy Other companies: Parabilis Medicines, Inc. (Lead Independent Director; Chairman, Nextech Invest; Chairman, Curie.Bio · Since at least Jun 9, 2026); Revolution Medicines, Inc. (Director · Since at least Jun 26, 2025); Blueprint Medicines Corp (Director · Since at least Jun 18, 2025); Tango Therapeutics, Inc. (Director · Since at least Jun 5, 2025) | Director · Since at least Jun 6, 2025 |
| Lonnel Coats Other companies: Mineralys Therapeutics, Inc. (Board Member · Since at least Oct 19, 2026); Verve Therapeutics Inc (Director · Since at least Aug 8, 2022); Blueprint Medicines Corp (Director · Since at least Feb 3, 2016); Lexicon Pharmaceuticals, Inc. (Chief Executive Officer, Director · Jul 7, 2014 – Feb 28, 2024 · Past) | Director · Since at least Nov 4, 2025 |
| Laura Shawver Other companies: ARS Pharmaceuticals, Inc. (Director · Since at least Dec 3, 2020); Nkarta, Inc. (Director · Jul 9, 2020 – Jun 8, 2022 · Past); Synthorx Inc (President and CEO, Director · Dec 6, 2018 – Jan 23, 2020 · Past) | Director · Jul 15, 2020 – Jun 3, 2024 · Past |
| Douglas S Ingram Other companies: Arrowhead Pharmaceuticals, Inc. (Director · Since at least Dec 16, 2025); Sarepta Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Dec 7, 2025) | Director · Since at least Jun 6, 2025 |
| Sanjiv K. Patel Other companies: ARYA Sciences Acquisition Corp V (Director · Jul 12, 2021 – Jul 12, 2021 · Past); Prothena Corporation plc (Director · May 19, 2021 – May 18, 2022 · Past) | President & Chief Executive Officer · Since at least Jul 15, 2020 |
| Sekar Kathiresan Other companies: Maze Therapeutics, Inc. (Director · Since at least Jan 30, 2025); Verve Therapeutics Inc (Chief Executive Officer, Director · Since at least Jun 16, 2021) | Director · Since at least Jul 25, 2022 |
| Claire Mazumdar Other companies: Bicara Therapeutics Inc. (Chief Executive Officer · Since at least Sep 12, 2024) | Director · Since at least Jun 9, 2025 |
| Andy Porter | Chief Administrative Officer · Dec 17, 2021 – Oct 28, 2022 · Past |
| Don Bergstrom | President, R&D · Since at least May 19, 2026 |
All 21 people
| Person | Seat |
|---|---|
| Eunice Kwak | SVP, Breast Cancer Global Medical Lead · Since at least Nov 5, 2026 |
| Imogen Pryce | Chief Operating Officer, R&D · Since at least Nov 5, 2026 |
| Jim Watters | Chief Scientific Officer · Since at least Nov 4, 2026 |
| Linda A Hill | Director · Since at least Jun 6, 2025 |
| Mahesh Padval | Chief Pharmaceutical Development Officer · Since at least Nov 5, 2026 |
| Mark Murcko | Director · Since at least Jun 3, 2024 |
| Peter Rahmer | Chief Corporate Development Officer · Since at least Dec 31, 2022 |
| Shannon Campbell | Head of Commercial · Since at least Nov 4, 2026 |
| Soo-Yeun Lim | Senior Vice President, General Counsel · Since at least Nov 5, 2026 |
| Thomas Catinazzo | Chief Financial Officer · Since at least Apr 28, 2022 |
| Tom Catinazzo | Chief Financial Officer · Since at least Oct 30, 2026 |
Log in to ask 6ix AI your own questions about Relay Therapeutics, Inc.